(MASS) 908 Devices - Ratings and Ratios
Handheld Mass Spectrometry, Desktop Mass Spectrometry, Optical Analyzer, Online Analyzer
MASS EPS (Earnings per Share)
MASS Revenue
Description: MASS 908 Devices October 28, 2025
908 Devices Inc. (NASDAQ:MASS) is a commercial-stage technology firm headquartered in Boston that designs and sells purpose-built handheld and desktop mass-spectrometry instruments for life-science research, bioprocessing, pharma/biopharma, forensics and related markets.
Its flagship products include the MX908 handheld mass spectrometer for rapid identification of solids, liquids, vapors and aerosols; the Rebel desktop analyzer that delivers real-time extracellular environment data for bioprocesses; and the Maverick optical in-line analyzer that monitors glucose, lactate, biomass and generates fingerprint data to support predictive bioprocess modeling. Complementary offerings such as Maven (online bioprocess monitoring), Trace C2 (methanol/ethanol feed control), and the ZipChip plug-and-play high-resolution separation platform round out the portfolio.
Recent financials show FY 2023 revenue of roughly $28 million, up about 42 % year-over-year, with a gross margin near 70 % and cash and equivalents of $45 million, giving the company a runway of over 18 months at current burn rates. The global mass-spectrometry market is projected to grow at a 7 % CAGR through 2030, driven by expanding biologics pipelines, tighter regulatory demands for real-time release testing, and increasing adoption of continuous biomanufacturing-trends that directly benefit 908 Devices’ core addressable market.
For a deeper quantitative dive into MASS’s valuation and peer benchmarks, the ValueRay platform provides a granular, data-driven analysis you may find useful.
MASS Stock Overview
| Market Cap in USD | 313m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2020-12-18 |
MASS Stock Ratings
| Growth Rating | -4.02% |
| Fundamental | 25.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 110% |
| Analyst Rating | 4.50 of 5 |
MASS Dividends
Currently no dividends paidMASS Growth Ratios
| Growth Correlation 3m | 69.2% |
| Growth Correlation 12m | 89.7% |
| Growth Correlation 5y | -89.3% |
| CAGR 5y | -16.99% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.19 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.28 |
| Sharpe Ratio 12m | 0.59 |
| Alpha | 129.56 |
| Beta | 0.456 |
| Volatility | 72.80% |
| Current Volume | 166.1k |
| Average Volume 20d | 266.7k |
| Stop Loss | 7.4 (-7.3%) |
| Signal | -0.15 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-18.4m TTM) > 0 and > 6% of Revenue (6% = 3.62m TTM) |
| FCFTA -0.15 (>2.0%) and ΔFCFTA -1.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 195.6% (prev 168.4%; Δ 27.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -28.7m <= Net Income -18.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (35.9m) change vs 12m ago 5.33% (target <= -2.0% for YES) |
| Gross Margin 48.59% (prev 49.65%; Δ -1.06pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.17% (prev 25.24%; Δ 4.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.38 (EBITDA TTM -60.7m / Interest Expense TTM -47.7m) >= 6 (WARN >= 3) |
Altman Z'' -6.98
| (A) 0.62 = (Total Current Assets 147.9m - Total Current Liabilities 29.7m) / Total Assets 191.7m |
| (B) -1.11 = Retained Earnings (Balance) -212.5m / Total Assets 191.7m |
| warn (B) unusual magnitude: -1.11 — check mapping/units |
| (C) -0.33 = EBIT TTM -65.8m / Avg Total Assets 200.2m |
| (D) -4.95 = Book Value of Equity -212.5m / Total Liabilities 42.9m |
| Total Rating: -6.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.31
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -14.71% = -5.0 |
| 3. FCF Margin -48.47% = -7.50 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.94 = 1.84 |
| 6. ROIC - WACC (= -55.36)% = -12.50 |
| 7. RoE -13.32% = -2.22 |
| 8. Rev. Trend 24.80% = 1.86 |
| 9. EPS Trend 16.64% = 0.83 |
What is the price of MASS shares?
Over the past week, the price has changed by -6.23%, over one month by -8.90%, over three months by +21.83% and over the past year by +154.55%.
Is 908 Devices a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MASS is around 7.65 USD . This means that MASS is currently overvalued and has a potential downside of -4.14%.
Is MASS a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MASS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | 25.3% |
| Analysts Target Price | 10 | 25.3% |
| ValueRay Target Price | 8.5 | 6.1% |
MASS Fundamental Data Overview October 18, 2025
P/S = 4.7777
P/B = 2.1217
Beta = 0.456
Revenue TTM = 60.4m USD
EBIT TTM = -65.8m USD
EBITDA TTM = -60.7m USD
Long Term Debt = 4.43m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 433.0k USD (from shortTermDebt, last quarter)
Debt = 4.43m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -57.3m USD (from netDebt column, last quarter)
Enterprise Value = 199.1m USD (313.2m + Debt 4.43m - CCE 118.6m)
Interest Coverage Ratio = -1.38 (Ebit TTM -65.8m / Interest Expense TTM -47.7m)
FCF Yield = -14.71% (FCF TTM -29.3m / Enterprise Value 199.1m)
FCF Margin = -48.47% (FCF TTM -29.3m / Revenue TTM 60.4m)
Net Margin = -30.53% (Net Income TTM -18.4m / Revenue TTM 60.4m)
Gross Margin = 48.59% ((Revenue TTM 60.4m - Cost of Revenue TTM 31.1m) / Revenue TTM)
Gross Margin QoQ = 48.89% (prev 47.05%)
Tobins Q-Ratio = 1.04 (Enterprise Value 199.1m / Total Assets 191.7m)
Interest Expense / Debt = -1076 % (Interest Expense -47.7m / Debt 4.43m)
Taxrate = -0.55% (negative due to tax credits) (71.0k / -12.8m)
NOPAT = -66.1m (EBIT -65.8m * (1 - -0.55%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.98 (Total Current Assets 147.9m / Total Current Liabilities 29.7m)
Debt / Equity = 0.03 (Debt 4.43m / totalStockholderEquity, last quarter 148.8m)
Debt / EBITDA = 0.94 (negative EBITDA) (Net Debt -57.3m / EBITDA -60.7m)
Debt / FCF = 1.96 (negative FCF - burning cash) (Net Debt -57.3m / FCF TTM -29.3m)
Total Stockholder Equity = 138.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.62% (Net Income -18.4m / Total Assets 191.7m)
RoE = -13.32% (Net Income TTM -18.4m / Total Stockholder Equity 138.5m)
RoCE = -46.03% (EBIT -65.8m / Capital Employed (Equity 138.5m + L.T.Debt 4.43m))
RoIC = -47.77% (negative operating profit) (NOPAT -66.1m / Invested Capital 138.5m)
WACC = 7.59% (E(313.2m)/V(317.7m) * Re(7.70%) + (debt cost/tax rate unavailable))
Discount Rate = 7.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 5.16%
Fair Price DCF = unknown (Cash Flow -29.3m)
EPS Correlation: 16.64 | EPS CAGR: 17.24% | SUE: 0.55 | # QB: 0
Revenue Correlation: 24.80 | Revenue CAGR: -6.75% | SUE: 0.81 | # QB: 0
Additional Sources for MASS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle